SEC For	rm 4 FORM	4 UI	NIT	TED STAT	۲E	S SECU	JRIT	IES /	AN	D EXCH	ANG	E COM	MIS	SIOI	N		
-						Washington, D.C. 20549										MB APPRO	VAL
to Sec obligat	this box if no lo tion 16. Form 4 tions may contin tion 1(b).	or Form 5	S	TATEMEN Filed	l pur	rsuant to Sec	ction 16	6(a) of t	he S	BENEFIC ecurities Excha nt Company A	ange Ac	t of 1934	RSI	HIP	Estima	Number: ated average burg per response:	3235-0287 den 0.5
ALTSH (Last) C/O VE	<u>IULER D</u> (Fir		(Middle)			VERTEX PHARMACEUTICALS INC / (Check all app MA [VRTX] Director X Office									or 10% Owner r (give title Other (specify		
50 NORTHERN AVENUE (Street) BOSTON MA 022				0	4.	. If Amendme	ent, Da	te of Original Filed (Month/Day/Y					Line) X Form file			oint/Group Filing (Check <i>I</i> led by One Reporting Pers led by More than One Rep	
(City)	(St	, ,	Zip)														
Ta 1. Title of Security (Instr. 3)			ble I - Non-Derivat 2. Transaction Date (Month/Day/Yea			2A. Deemed Execution Date,		3. Transaction Code (Instr.		4. Securities Disposed O	A. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar			d 5) Securities Beneficial Owned Fo		6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership
								Code	v	Amount	(A) or (D)	Price		Report Transa (Instr.	ed ction(s) 3 and 4)	(Instr. 4)	(Instr. 4)
Common Stock				02/24/2023				F		3,970	D	\$289.	89.12 3		6,276	D	
Common Stock				02/27/2023				S ⁽¹⁾		3,636	D	\$287.23	.23 ⁽²⁾⁽³⁾		2,640	D	
Common Stock				02/27/2023				S ⁽¹⁾		300	D	\$288.74	.74 ⁽²⁾⁽⁴⁾		2,340	D	
Common Stock 02/27/2023					3			S ⁽¹⁾		302	D	\$289.6	39.6 ⁽²⁾⁽⁵⁾		2,038	D	
		Tal	ble	II - Derivati (e.g., pu	ive ıts,	Securitie , calls, wa	es Ac arran	quire ts, op	d, E tioi	Disposed o ns, conver	f, or E tible s	Beneficia securities	ully (s)	Owneo	ł		
1. Title of Derivative Security (Instr. 3)			ecution Date,		5. Numb of Dede (Instr. Acquire (A) or Dispose of (D) (Instr. 3, and 5)		ve (Mo es d	pirati	Exercisable an ion Date Day/Year)	d 7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Der Sec	8. Price of Derivative Security (Instr. 5) Benefic Owned Followi Report Transa (Instr. 4		Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownershi (Instr. 4)	

Explanation of Responses:

1. Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1.

2. Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

(D)

(A)

v

Code

Date Exercisable

Expiration Date

3. Open market sales reported on this line occurred at a weighted average price of \$287.23 (range \$286.80 to \$287.72).

4. Open market sales reported on this line occurred at a weighted average price of \$288.74 (range \$288.42 to \$289.37).

5. Open market sales reported on this line occurred at a weighted average price of \$289.60 (range \$289.49 to \$289.65).

Remarks:

/s/ Joy Liu, Attorney-in-Fact 02/28/2023

Amount or Number

of Shares

Title

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.